重度のうつ病における不眠症に対するミルタザピンの治療効果と安全性: 6週間のオープンラベル介入前および介入後試験の結果
Neuropsychobiology
|September 2, 2025
まとめ
ミルタザピンは重度のうつ病 (MDD) の患者で不眠症とうつ病の症状を有意に改善しました. 治療により生活の質が向上し,食欲が高まり,体重増加が一般的な副作用となりました.
科学分野:
- 精神科
- 薬理学について
- 臨床医学
背景:
- 不眠症は,大うつ病 (MDD) の一般的な症状であり,大人の患者の約75%に影響します.
- 不眠症は,うつ病の症状の寛解後でも持続し,効果的な治療戦略の必要性を強調します.
研究 の 目的:
- MDD患者における不眠症とうつ病の重度の軽減におけるミルタサピンの有効性を評価する.
- ミルタザピンの副作用を評価し,治療前と後の生活の質の変化を比較する.
主な方法:
- 6週間の単一センターでの オープン・ラベル 準実験的な介入前後試験です
- ハミルトンうつ病評価スケール (HDRS),不眠症重症指数 (ISI),抗うつ薬副作用チェックリスト (ASEC),WHOQOL-BREFを使用した.
主要な成果:
- ミルタザピン治療は不眠症 (ISIスコア) とうつ病 (HDRSスコア) の両方を有意に減少させた.
- 6週目までに,患者の62. 4%が不眠症の寛解を達成し,41. 3%がうつ病の寛解を達成した.
- 一般的な副作用には食欲増加,眠気,体重増加が挙げられ,生活の質のあらゆる分野において有意な改善が認められた.
結論:
- ミルタザピンは,MDD患者におけるうつ病,不眠症,および生活の質の改善に有効です.
- 食欲の増加と体重増加は,注目すべき副作用であり,モニタリングが必要です.
- 不眠症のMDD患者の臨床ケアを最適化するために,さらなるランダム化制御試験が推奨されています.
関連する概念動画
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
238
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
238
01:19Management of Insomnia
320
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
320
01:23Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
563
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
563
01:23Sedatives and Hypnotics: Overview
636
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
636
01:14CNS Depressants: Barbiturates and Benzodiazepines
466
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
466